Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lactic acid + citric acid + potassium bitartrate** is a prescription, non-hormonal contraceptive vaginal gel marketed in the United States as **Phexxi** for prevention of pregnancy in females of reproductive potential. Developed by **Evofem Biosciences**, it is a combination small-molecule drug product administered intravaginally using a pre-filled applicator immediately before, or up to one hour before, each act of vaginal intercourse. Its contraceptive effect is achieved by maintaining the vaginal environment in an acidic pH range that is inhospitable to sperm and reduces sperm motility, rather than through systemic hormonal activity or a specific molecular receptor target. The product is minimally systemically absorbed and common adverse reactions include vulvovaginal burning, pruritus, urinary tract infection, and bacterial vaginosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactic acid + citric acid + potassium bitartrate.